View in EDS HTML Full Text PDF Full Text

Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223.

Saved in:
Bibliographic Details
Title: Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223.
Authors: Caffo, Orazio1 (AUTHOR) orazio.caffo@apss.tn.it, Frantellizzi, Viviana2 (AUTHOR), Tucci, Marcello3 (AUTHOR), Galli, Luca4 (AUTHOR), Monari, Fabio5 (AUTHOR), Baldari, Sergio6 (AUTHOR), Masini, Cristina7 (AUTHOR), Bortolus, Roberto8 (AUTHOR), Facchini, Gaetano9 (AUTHOR), Alongi, Pierpaolo10 (AUTHOR), Agostini, Stefania11 (AUTHOR), Zichi, Clizia3 (AUTHOR), Biasco, Elisa4 (AUTHOR), Fanti, Stefano12 (AUTHOR), Pignata, Salvatore6 (AUTHOR), Filice, Angelina13 (AUTHOR), Borsatti, Eugenio14 (AUTHOR), Rossetti, Sabrina9 (AUTHOR), Spada, Massimiliano15 (AUTHOR), Cortesi, Enrico2 (AUTHOR)
Source: European Journal of Nuclear Medicine & Molecular Imaging. Oct2020, Vol. 47 Issue 11, p2633-2638. 6p. 2 Charts.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:16197070
DOI:10.1007/s00259-020-04796-w